文献速递浆细胞疾病

解析多发性骨髓瘤局灶性病变肿瘤微环境中的中性粒细胞动态以克服免疫抑制

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

研究通过单细胞RNA测序、免疫荧光成像和功能实验分析多发性骨髓瘤患者配对局灶性病变与骨髓的新鲜分离髓系细胞,识别出3个CXCR2+成熟中性粒细胞亚群,其中TREM1+CD10+亚群在局灶性病变中高 prevalence 并对T细胞有强免疫抑制作用,其基因特征与更短总生存相关;CXCR2阻断可减少临床前模型的肿瘤负荷并改善总生存。

要点

  • 鉴定出3个CXCR2+成熟中性粒细胞亚群:TREM1+CD10+、RETN+LCN2+和TNFAIP3+CXCL8+。
  • TREM1+CD10+亚群在局灶性病变中高度流行,对T细胞有强免疫抑制作用。
  • TREM1+CD10+亚群基因特征与多发性骨髓瘤患者更短总生存相关。

核心结论

  • 多发性骨髓瘤肿瘤微环境中存在3个CXCR2+成熟中性粒细胞亚群,其中TREM1+CD10+亚群具有强免疫抑制作用并与更短总生存相关。
  • 通过CXCR2阻断靶向抑制中性粒细胞活性,单独或联合标准抗多发性骨髓瘤治疗,在临床前多发性骨髓瘤模型中显著减少肿瘤负荷并改善总生存。

研究设计与样本

  • 研究分析多发性骨髓瘤患者配对局灶性病变和骨髓中新分离的髓系细胞,采用单细胞RNA测序、免疫荧光成像和功能实验。

主要发现

  • 描述3个CXCR2+成熟中性粒细胞亚群:TREM1+CD10+、RETN+LCN2+和TNFAIP3+CXCL8+,每个亚群在肿瘤微环境中表现出独特表型。
  • TREM1+CD10+亚群高度流行,尤其在局灶性病变中,对T细胞表现出强免疫抑制作用。
  • TREM1+CD10+亚群的基因特征在大型多发性骨髓瘤患者数据集中与更短总生存相关。
  • 通过CXCR2阻断靶向抑制中性粒细胞活性,单独或联合标准抗多发性骨髓瘤治疗,在临床前多发性骨髓瘤模型中显著减少肿瘤负荷并改善总生存。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Understanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppressive barriers protecting multiple myeloma (MM). Neutrophils are a new cancer research focus due to their potential to reduce the efficacy of immune-based therapies. This study aimed to deepen understanding of neutrophil function in MM by analyzing freshly isolated myeloid cells from paired focal lesions (FLs) and bone marrow using single-cell RNA sequencing, immunofluorescence imaging, and functional assays. We describe 3 distinct CXCR2+ mature neutrophil subsets: TREM1+CD10+, RETN+LCN2+, and TNFAIP3+CXCL8+, each exhibiting unique phenotypes within the TME. Notably, the TREM1+CD10+ subset was highly prevalent, particularly in FLs, demonstrating potent immunosuppressive effects on T cells. This subset's gene signature was correlated with shorter overall survival (OS) in a large data set of patients with MM, underscoring its clinical significance. Targeted inhibition of neutrophil activity through CXCR2 blockade, alone or combined with standard anti-MM therapies, significantly reduced tumor burden, improving OS in preclinical MM models. These insights into neutrophil-mediated immunosuppression in MM provide valuable knowledge regarding mechanisms driving immune evasion, and reveal new therapeutic approaches to enhance the efficacy of MM treatment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rivera J, Yan Q, Daneshmandi S, et al. Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma. Blood. 2025. PMID: 40758944. doi:10.1182/blood.2025028963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。